OPİYAT BAĞIMLILIĞI İLE TAKİP EDİLEN HASTADA ATOMOKSETİN KULLANIMININ NÖROPSİKOMETRİK TESTLERE YANSIMASI: OLGU SUNUMU

Yıl 2020, Cilt: 4 Sayı: 1, 35 - 39, 07.04.2020

Müberra Kulu Filiz Özsoy

https://doi.org/10.5455/car.105-1594640113

Öz

Alkol/madde kullanım bozukluğu ve dikkat eksikliği ve hiperaktivite bozukluğu (DEHB) birlikteliği sıklıkla bildirilen bir durumdur. Bu iki hastalığın birlikteliği hem tedaviye uyumunu bozan, hem de mortalite ve morbidite oranlarını arttıran bir durumdur. DEHB tedavisinde kullanılan medikal tedavilerin kötüye kullanılma potansiyellerinden dolayı tedavi seçenekleri de oldukça kısıtlı olmaktadır. Bu yazıda atomoksetin tedavisi ile opiyat kullanım bozukluğu tanısı olan bir hastada gözlenen dikkat eksikliği semptomlarının gerilemesi ve hastaya uygulanan nöropsikometrik test sonuçlarındaki düzelmeler aktarılacaktır.

Anahtar Kelimeler

dikkat eksikliği, opiyat kullanım bozukluğu, nöropsikometrik testler, atomoksetin

Kaynakça

• 1- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington DC: American Psychiatric Association Publishing; 2013.
• 2- Baykara S, Atmaca M. Erkek opiyat kullanım bozukluğu hastalarında kendine zarar verici davranış ve intihar girişimi öyküsünün dürtüsellik ve bazı klinik verilerle ilişkisi. Anadolu Psikiyatri Dergisi 2019; 20(1): 29-37.
• 3- Tarabar AF, Nelson LS. The resurgence and abuse of heroin by children in the United States. Curr Opin Pediatr. 2003;15:210-5.
• 4- Bailey A, Yuferov V, Bendor J, Schlussman SD, Zhou Y, Ho A, Kreek JM. Immediate withdrawal from chronic “binge” cocaine administration increases mu-opioid receptor mRNA levels in rat frontal cortex. Mol Brain Res. 2005;137:258–62.
• 5- Evren C, Uluğ B. Alkol Madde Bağımlılığı Tanı ve Tedavi El Kitabı. 2012.
• 6- Sadock BJ, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Science/Clinical Psychiatry. Günes Kitapevi Ltd.Sti, Lippincott Williams & Wilkins, 11. Baskı, 2015;616-94.
• 7- George O, Koob GF. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2010;35:232-47.
• 8- Evren C. Alkol ve Madde Kullanım Bozuklukları Temel Başvuru Kitabı. 2019, Ankara: TPD.
• 9- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM5). Diagn Stat Man Ment Disord 4th ed TR. 2013; p.280.
• 10- Anastopoulos AD, Smith TF, Garrett ME, Morrissey-Kane E, Schatz NK, Sommer JL, et al. Self-Regulation of Emotion, Functional Impairment, and Comorbidity Among ChildrenWith AD/HD. J Atten Disord. 2011;15(7):583-92.
• 11- Kim S, Kim M-S. Deficits in Verbal Working Memory among College Students with Attention-Deficit/Hyperactivity Disorder Traits: An Event-related Potential Study. Clin Psychopharmacol Neurosci. 2016;14(1):64-73.
• 12- Kafalı HY, Özbaran B. Bağımlılıkta Riskli Bir Durum: Dikkat Eksikliği Hiperaktivite Bozukluğu, Tanı,Tedavi ve Vaka Yönetimi. Turkiye Klinikleri Child Psychiatry-Special Topics. 2019;5(2):25-33.
• 13- Wilson JJ, Levin FR. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol. 2005;15(5):751-63.
• 14- Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643-62.
• 15- Karakaş S, Erdoğan E, Sak L, Soysal AŞ, Ulusoy T, Ulusoy İY, et al. Stroop Test TBAG Form: Standardisation for Turkish Culture, Reliability and Validity. J Clin Psy. 1999;2(2):75-88.
• 16- Türkbay T. Dikkat Eksikliği ve Aşırı Hareketlilik Bozukluğu ile birliktelik gösteren bozukluklar. SAPİENS Özel Eğitim ve Rehabilitasyon Dergisi. 2006;2:26-9.
• 17- Sundquist J, Ohlsson H, Sundquist K, Kendler KS. Attention-deficit/hyperactivity disorder and risk for drug use disorder: A population-based follow-up and co-relative study. Psychol Med. 2015;45(05):977–83.
• 18- Skoglund C, Chen Q, Franck J, Lichtenstein P, Larsson H. Attention-deficit/hyperactivity disorder and risk for substance use disorders in relatives. Biol Psychiatry. 2015;77(10):880–6.
• 19- Quinn PD, Pettersson E, Lundström S, Anckarsäter H, Långström N, Gumpert CH, et al. Childhood attention-deficit/hyperactivity disorder symptoms and the development of adolescent alcohol problems: A prospective, population-based study of Swedish twins. Am J Med Genet Part B. 2016;171(7):958–70.
• 20- Dalsgaard S, Øtergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study. Lancet. 2015;385(9983):2190–6.
• 21- Philipsen A, Jans T, Graf E, Matthies S, Borel P, Colla M, et al. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention- deficit/hyperactivity disorder: A randomized clinical trial. JAMA Psychiatry. 2015;72(12):1199– 210.
• 22- Subcommittee on Attention-Deficit/Hyperactivity Disorder: Steering Committee on Quality Improvement and Management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–22
• 23- Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey BB, Rickert ME, et al. ADHD medication and substance-related problems. Am J Psychiatry, 2017;174(9):877- 85.
• 24- Cunill R, Castells X, Tobias A, Capellà D. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol. 2015;29:15-23.
• 25- Crunelle CL, Van Den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur Addiction Res. 2018;24(1):43-51.
• 26- Carpentier PJ, van Gogh MT, Knapen LJM, Buitelaar JK, De Jong CAJ. Influence of Attention Deficit Hyperactivity Disorder and Conduct Disorder on Opioid Dependence Severity and Psychiatric Comorbidity in Chronic Methadone-Maintained Patients. Eur Addict Res. 2011;17(1):10-20.
• 27- Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96(1-2):145-54.
• 28- Thurstone C, Riggs PD, Salomonsen-Sautel S, Mikulich-Gilbertson SK. Randomized, Controlled Trial of Atomoxetine for AttentionDeficit/Hyperactivity Disor der in Adolescents With Substance Use Disorder. J AmAcad Child Adolesc Psychiatry. 2010;49(6):573-82.
• 29- Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J A m Acad Child Adolesc Psychiatry. 2011;50(9): 903-14.
• 30- Simon N, Rolland B, Karila L. Methylphenidate in adults with attention deficit hyperactivity disorder and substance use disorders. Curr Pharm Des. 2015;21:3359- 66.
• 31- Skoglund C, Brandt L, Almqvist C, D’Onofrio BM, Konstenius M, Franck J, et al. Factors associated with adherence to methylphenidate treatment in adult patients with attention deficit/hyperactivity disorder and substance use disorders. J Clin Psychopharmacol. 2016;36(3):222.